Valuation: Halozyme Therapeutics, Inc.

Market Cap 11.43B 9.9B 9.28B 8.47B 15.93B 1,090B 16.18B 109B 42.68B 546B 42.9B 41.97B 1,821B P/E 2026 *
14x
P/E 2027 * 11.2x
Enterprise Value 12.77B 11.07B 10.38B 9.46B 17.8B 1,219B 18.09B 122B 47.7B 610B 47.94B 46.9B 2,035B EV / Sales 2026 *
6.89x
EV / Sales 2027 * 5.73x
Free-Float
98.89%
Yield 2026 *
-
Yield 2027 * -
1 day-1.10%
1 week+17.39%
Current month+21.97%
1 month+32.27%
3 months+43.75%
6 months+26.72%
Current year+49.58%
1 week 99.41
Extreme 99.41
104.78
1 month 73.89
Extreme 73.8901
104.78
Current year 61.32
Extreme 61.325
104.78
1 year 61.22
Extreme 61.225
104.78
3 years 32.83
Extreme 32.83
104.78
5 years 29.85
Extreme 29.85
104.78
10 years 8.18
Extreme 8.18
104.78
Manager TitleAgeSince
Chief Executive Officer 63 2014-01-05
Director of Finance/CFO 61 2013-04-30
Director of Finance/CFO - 2026-06-07
Director TitleAgeSince
Director/Board Member 59 2013-03-27
Director/Board Member 63 2014-01-05
Chairman 61 -
Date Insider Type Main position Quantity % Market Cap.
8/10/26 Sell

Director

-1,626 0.0014%
7/8/26 Fiscal year

Chief Executive Officer

5,769 0.0049%
7/1/26 Free

Executive/Senior Manager

56,055 0.0473%
Change 5-day change 1-year change 3-year change Capi.($)
-1.10%+17.39%+54.57%+130.10% 11.43B
+1.98%+5.59%+63.89%+26.16% 334B
-1.51%-4.21%+24.02%-15.35% 69.97B
-1.26%+1.30%-1.92%-3.41% 8.58B
-0.68%+4.91%-12.57%-7.50% 4.84B
-0.72%+6.04%-27.25%+14.43% 4.34B
+1.29%+11.53%-0.90%+49.99% 4.27B
-1.50%+0.83%+10.58%+47.85% 2.74B
-0.28%+2.94%-5.19%-1.42% 2.23B
+1.73%+15.02%-24.31%+50.07% 2.05B
Average -0.20%+2.98%+8.09%+29.09% 44.49B
Weighted average by Cap. +1.21%+4.16%+52.68%+21.59%

Financials

2026 *2027 *
Net sales 1.85B 1.61B 1.51B 1.37B 2.58B 177B 2.63B 17.74B 6.92B 88.56B 6.96B 6.81B 295B 2.05B 1.78B 1.67B 1.52B 2.86B 196B 2.9B 19.62B 7.66B 97.97B 7.7B 7.53B 327B
Net income 869M 753M 706M 644M 1.21B 82.91B 1.23B 8.31B 3.24B 41.5B 3.26B 3.19B 138B 1.07B 926M 868M 791M 1.49B 102B 1.51B 10.22B 3.99B 51.02B 4.01B 3.92B 170B
Net Debt 1.34B 1.16B 1.09B 996M 1.87B 128B 1.9B 12.86B 5.02B 64.21B 5.05B 4.94B 214B 320M 277M 260M 237M 445M 30.49B 453M 3.06B 1.19B 15.26B 1.2B 1.17B 50.92B
Logo Halozyme Therapeutics, Inc.
Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing solutions to improve patient experiences and outcomes for emerging and established therapies. The Company's commercially-validated solution, ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, is used to facilitate the subcutaneous delivery of injected drugs and fluids, with a focus on improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. The Company licenses its technology to biopharmaceutical companies to collaboratively develop products that combine ENHANZE with its partners’ proprietary compounds. It also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The Company has two commercial proprietary products, Hylenex and XYOSTED. It also has a proprietary ultra-high concentration microparticle formulation technology for biologics, branded Hypercon.
Employees
423
Date Price Change Volume
26-08-13 US$100.67 -1.10% 1,982,780
26-08-12 US$101.79 -0.81% 3,650,585
26-08-11 US$102.62 0.00% 2,846,031
26-08-10 US$102.62 -0.48% 4,934,990
26-08-07 US$103.12 +20.24% 7,691,625
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
100.67USD
Average target price
99.56USD
Spread / Average Target
-1.11%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. HALO Stock